Post-event follow-up costs in patients with atherosclerotic cardiovascular disease in Spain
Ver/ Abrir
Impacto
Scholar |
Otros documentos de la autoría: Martínez López, Icíar; GOMEZ CEREZO, JORGE FRANCISCO; Gámez, José Mª; Egocheaga Cabello, Isabel; Castellanos, María del Mar; Campuzano Ruiz, Raquel; barrios, vivencio; Pallarés-Carratalá, Vicente; Rodríguez, José Manuel; Morant Talamante, Nuria; Parrondo, Javier; Mostaza, José María
Metadatos
Mostrar el registro completo del ítemcomunitat-uji-handle:10234/9
comunitat-uji-handle2:10234/36080
comunitat-uji-handle3:10234/36082
comunitat-uji-handle4:
INVESTIGACIONMetadatos
Título
Post-event follow-up costs in patients with atherosclerotic cardiovascular disease in SpainAutoría
Fecha de publicación
2024Editor
FrontiersISSN
2297-055XCita bibliográfica
Martínez López I, Gómez Cerezo JF, Gámez JM, Egocheaga Cabello I, Castellanos M, Campuzano Ruiz R, Barrios V, PallarésCarratalá V, Rodríguez JM, Morant Talamante N, Parrondo J and Mostaza JM (2024) Post-event follow-up costs in patients with atherosclerotic cardiovascular disease in Spain. Front. Cardiovasc. Med. 11:1324537. doi: 10.3389/fcvm.2024.1324537Tipo de documento
info:eu-repo/semantics/articleVersión
info:eu-repo/semantics/publishedVersionPalabras clave / Materias
Resumen
Introduction: Atherosclerotic cardiovascular disease (ASCVD) is one of the main
causes of morbidity and mortality in developed countries and entails high
resources use and costs for health systems. The risk of ... [+]
Introduction: Atherosclerotic cardiovascular disease (ASCVD) is one of the main
causes of morbidity and mortality in developed countries and entails high
resources use and costs for health systems. The risk of suffering future
cardiovascular (CV) events and the consequent resources use is higher in those
patients who have already had a previous cardiovascular event. The objective of
the study was to determine the average annual cost of patients with a new or
recurrent atherosclerotic CV event during the 2 years after the event.
Methodology: Retrospective observational study of electronic medical records
of patients from the BIG-PAC® database (7 integrated health areas of 7
Autonomous Communities; n = 1.8 million). Patients with a new or recurrent
episode of ASCVD (angina, acute myocardial infarction, transient ischemic
attack, stroke, or peripheral arterial disease) between 1-Jan-2017 and 31-Dec2018 were included. The resources use within two years of the diagnosis was
estimated in order to estimate the average cost of patient follow-up.
Results: A total of 26,976 patients with an ASCVD episode were identified during
the recruitment period; Out of them, 6,798 had a recurrent event during the
follow-up period and 2,414 died. The average costs per patient were €11,171
during the first year and €9,944 during the second year.
Discussion: Patients with ASCVD represent a significant economic burden for the
health system and for society. Despite the perception that drug costs in the followup of chronic patients imply a high percentage of the costs, these accounted for only
one tenth of the total amount. Implementing preventive programs and increasing the
control of cardiovascular risk factors may have a significant social and health impact
by helping to reduce mortality and costs for the Spanish National Health System. The
costs derived from pharmacological treatments were obtained from the NHS pricing
nomenclator database (https://www.sanidad.gob.es/profesionales/nomenclator.do). [-]
Publicado en
Frontiers in Cardiovascular Medicine 11:1324537Derechos de acceso
info:eu-repo/semantics/openAccess
Aparece en las colecciones
- MED_Articles [660]